US20200085902A1 - Composition and method for treating itching, burning and discomfort of the skin - Google Patents

Composition and method for treating itching, burning and discomfort of the skin Download PDF

Info

Publication number
US20200085902A1
US20200085902A1 US16/664,477 US201916664477A US2020085902A1 US 20200085902 A1 US20200085902 A1 US 20200085902A1 US 201916664477 A US201916664477 A US 201916664477A US 2020085902 A1 US2020085902 A1 US 2020085902A1
Authority
US
United States
Prior art keywords
weight
percent
present
amount
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/664,477
Inventor
Kenneth Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/664,477 priority Critical patent/US20200085902A1/en
Publication of US20200085902A1 publication Critical patent/US20200085902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention generally relates to the treatment of pruritus, more specifically relates to topical composition and method for alleviating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
  • Pruritus refers to an unpleasant sensation on the skin that urges to scratch or rub the area in order to obtain relief. Pruritus is commonly characterized by generalized and localized itching. Itching may be caused as a clinical manifestation of localized skin disorder, systemic disease, scratch reaction, insect bite, sunburn, wound healing and exposure to irritants such as plant toxins, chemicals, microbial proteins, and/or additional external mechanical, thermal and electrical stimuli. Common types of itching include anal itch, chemical itch, eczema, (including seborrheic dermatitis) pruritus dermatitis, diabetic skin itch, aging skin itch, foot-itch, jock itch, hives, dry winter skin itch and stress related scalp itch.
  • pruritus can also occur in non-cutaneous sites such as mucous membranes.
  • Perianal itching or “Pruritus ani” refers to the persistent itching and irritation of skin around the anus region. Perianal itching and burning not only causes physical discomfort but also results in distraction and socially awkward or embarrassing situations. Anal itching may be caused by chemical irritants in food, diarrhea, psoriasis, anal fissure, hemorrhoids, skin tags, diabetes, yeast infection and pinworm infection.
  • topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy.
  • topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy.
  • Treatment with existing topical agents shows general but nonspecific benefit.
  • Non-specific topical preparations including lotions, creams and oil-based ointments may provide softness and moisturizing effect on the dry skin, but causes an uncomfortable feeling and discomfort due to greasy nature of the preparation and soiling of garments.
  • existing topical agents used for relieving perianal pruritus act slow and fail to provide complete cure from itching and burning.
  • the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
  • the composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.
  • the present invention relates to a composition for treating localized pruritus.
  • the composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel (0-50%), Hamamelis virginiana extract (0-50%), deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol in amounts up to 3 percent by weight.
  • the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
  • the method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract, 0 to 3% deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
  • the present invention relates to a topical composition for treating discomfort of the skin and/or mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel.
  • the hydrocortisone is present in an amount up to 1 percent by weight.
  • the Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight.
  • the Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight.
  • the present invention relates to a pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream.
  • the aloe leaf gel and witch hazel extract are both present in an amount up to 50 percent by weight.
  • the green tea leaf extract and vitamin E are both present in an amount up to 3 percent by weight.
  • the hydrocortisone is present in an amount up to 1 percent by weight.
  • active agent drug
  • active compound active compound
  • pharmacologically active agent refers to a chemical material or compound which, when administered to humans, induces a desired pharmacologic effect. Included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids; acid addition salts formed with organic acids; or salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, aluminum ion; or coordinates with an organic base such as ethanolamine, and the like.
  • a metal ion e.g., an alkali metal ion, aluminum ion
  • coordinates with an organic base such as ethanolamine, and the like.
  • carrier or “carrier” is composed of materials that are present in pharmaceutical formulation other than the active ingredient. Carriers are considered safe and effective and may be administered to an individual without causing undesirable biological side effects.
  • carrier includes, but is not limited to, excipients, diluents, binders, lubricants, disintegrators, fillers, gliding agent and coating compositions.
  • the present invention relates to a pharmaceutical composition for treating anal pruritus.
  • the pharmaceutical composition comprises at least one active agent or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier.
  • the composition is used for rapidly alleviating external anal itching and burning in humans.
  • the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
  • the composition consisting essentially of Aloe leaf gel, deionized water, C12-15 alkyl benzoate, Green tea leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Witch Hazel extract, Sunflower seed oil, polyethylene glycol(PEG)-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate (Vitamin E), Zemea propanediol and hydrocortisone.
  • the Aloe leaf gel of the composition is obtained from Aloe barbadensis leaves.
  • Green tea leaf extract is obtained from Camellia sinensis leaves.
  • Witch Hazel extract comprises an extract of Hamamelis virginiana and Sunflower seed oil is obtained from Helianthus annus seeds.
  • the present invention relates to a composition for treating localized anal pruritus.
  • the composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel, and Hamamelis virginiana extract are in amounts up to 50 percent by weight.
  • Other components such as deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol are in amounts up to 3 percent by weight.
  • the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
  • the method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract and 0 to 3% by weight deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
  • the composition is prepared in a form suitable for topical application on the skin surface of perianal region.
  • the composition can be prepared in the form of cream, spray, lotion, solution, gel, emollient, ointment and aerosol form for application on the external perianal area of human body in order to alleviate itching.
  • composition of the present invention is formulated in the form of a topical cream, which comprises the active agent and pharmaceutically acceptable carriers in a specific percent by weight ratio as mentioned in Table 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis (aloe vera) leaf gel, Camellia sinensis leaf (green tea) extract, Hamamelis virginiana (witch hazel) extract, tocopheryl acetate (vitamin E), and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of co-pending U.S. application Ser. No. 15/217,721, filed Jul. 22, 2016, expected to issue as U.S. Pat. No. 10,456,438 on Oct. 29, 2019.
  • FIELD OF THE INVENTION
  • The present invention generally relates to the treatment of pruritus, more specifically relates to topical composition and method for alleviating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
  • BACKGROUND
  • “Pruritus” refers to an unpleasant sensation on the skin that urges to scratch or rub the area in order to obtain relief. Pruritus is commonly characterized by generalized and localized itching. Itching may be caused as a clinical manifestation of localized skin disorder, systemic disease, scratch reaction, insect bite, sunburn, wound healing and exposure to irritants such as plant toxins, chemicals, microbial proteins, and/or additional external mechanical, thermal and electrical stimuli. Common types of itching include anal itch, chemical itch, eczema, (including seborrheic dermatitis) pruritus dermatitis, diabetic skin itch, aging skin itch, foot-itch, jock itch, hives, dry winter skin itch and stress related scalp itch. Those who suffer from itch often note, persistent or recurrent attacks. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes. “Perianal itching” or “Pruritus ani” refers to the persistent itching and irritation of skin around the anus region. Perianal itching and burning not only causes physical discomfort but also results in distraction and socially awkward or embarrassing situations. Anal itching may be caused by chemical irritants in food, diarrhea, psoriasis, anal fissure, hemorrhoids, skin tags, diabetes, yeast infection and pinworm infection.
  • Current treatment options for localized pruritus including perianal itching involves the use of topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy. However, treatment with existing topical agents shows general but nonspecific benefit. Non-specific topical preparations including lotions, creams and oil-based ointments may provide softness and moisturizing effect on the dry skin, but causes an uncomfortable feeling and discomfort due to greasy nature of the preparation and soiling of garments. In addition, existing topical agents used for relieving perianal pruritus act slow and fail to provide complete cure from itching and burning.
  • Therefore, there is a need for an improved topical pharmaceutical preparation for providing rapid relief from pruritus by alleviating itching and burning in the perianal region of humans. There is also a need for improved composition and method for treating pruritus of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
  • SUMMARY OF THE INVENTION
  • The present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.
  • In an embodiment, the present invention relates to a composition for treating localized pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel (0-50%), Hamamelis virginiana extract (0-50%), deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol in amounts up to 3 percent by weight.
  • In an embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract, 0 to 3% deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
  • In an embodiment, the present invention relates to a topical composition for treating discomfort of the skin and/or mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The hydrocortisone is present in an amount up to 1 percent by weight. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight.
  • In an embodiment, the present invention relates to a pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream. The aloe leaf gel and witch hazel extract are both present in an amount up to 50 percent by weight. The green tea leaf extract and vitamin E are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • The terms “active agent,” “drug”, “active compound” and “pharmacologically active agent” are used interchangeably herein to refer to a chemical material or compound which, when administered to humans, induces a desired pharmacologic effect. Included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids; acid addition salts formed with organic acids; or salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, aluminum ion; or coordinates with an organic base such as ethanolamine, and the like.
  • Pharmaceutically acceptable “carrier” or “carrier” is composed of materials that are present in pharmaceutical formulation other than the active ingredient. Carriers are considered safe and effective and may be administered to an individual without causing undesirable biological side effects. The term “carrier” includes, but is not limited to, excipients, diluents, binders, lubricants, disintegrators, fillers, gliding agent and coating compositions.
  • The present invention relates to a pharmaceutical composition for treating anal pruritus. The pharmaceutical composition comprises at least one active agent or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier. The composition is used for rapidly alleviating external anal itching and burning in humans.
  • In an embodiment, the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe leaf gel, deionized water, C12-15 alkyl benzoate, Green tea leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Witch Hazel extract, Sunflower seed oil, polyethylene glycol(PEG)-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate (Vitamin E), Zemea propanediol and hydrocortisone.
  • In an embodiment, the Aloe leaf gel of the composition is obtained from Aloe barbadensis leaves. Green tea leaf extract is obtained from Camellia sinensis leaves. Witch Hazel extract comprises an extract of Hamamelis virginiana and Sunflower seed oil is obtained from Helianthus annus seeds.
  • The present invention relates to a composition for treating localized anal pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel, and Hamamelis virginiana extract are in amounts up to 50 percent by weight. Other components such as deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol are in amounts up to 3 percent by weight.
  • In another embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract and 0 to 3% by weight deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
  • The composition is prepared in a form suitable for topical application on the skin surface of perianal region. The composition can be prepared in the form of cream, spray, lotion, solution, gel, emollient, ointment and aerosol form for application on the external perianal area of human body in order to alleviate itching.
  • EXAMPLE 1
  • In this exemplary embodiment, the composition of the present invention is formulated in the form of a topical cream, which comprises the active agent and pharmaceutically acceptable carriers in a specific percent by weight ratio as mentioned in Table 1.
  • TABLE 1
    Ingredient Ratio (Percent by Ingredient Weight)
    Hydrocortisone 0 to 1
    Hamamelis virginiana extract  0 to 50
    Camellia sinensis leaf extract 0 to 3
    Tocopheryl acetate (Vitamin E) 0 to 3
    Aloe barbadensis juice  0 to 50
    Helianthus annuus seed oil 0 to 3
    Cetyl alcohol 0 to 3
    Glycerin stearate 0 to 3
    Ceteareth-20 0 to 3
    Stearyl alcohol 0 to 3
    C12-15 alkyl benzoate 0 to 3
    Cetearyl alcohol 0 to 3
    Zemea propanediol 0 to 3
    Phenoxyethanol 0 to 3
    PEG-100 stearate 0 to 3
    Ethylexylglycerin 0 to 3
    Petrolatum 0 to 3
    Aqua (deionized water) 0 to 3
  • Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific examples and studies detailed above are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

Claims (15)

What is claimed is:
1. A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel.
2. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight.
3. The topical composition of claim 1 wherein the Hamamelis virginiana extract is present in an amount up to 50 percent by weight.
4. The topical composition of claim 1 wherein the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight.
5. The topical composition of claim 1 wherein the tocopheryl acetate is present in an amount up to 3 percent by weight.
6. The topical composition of claim 1 wherein hydrocortisone is present in an amount up to 1 percent by weight.
7. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight, the Hamamelis virginiana extract is present in an amount up to 50 percent by weight, the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight, the tocopheryl acetate is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
8. A pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream, lotion, emollient, ointment, spray, aerosol or gel.
9. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight.
10. The topical composition of claim 8 wherein the witch hazel extract is present in an amount up to 50 percent by weight.
11. The topical composition of claim 8 wherein the green tea leaf extract is present in an amount up to 3 percent by weight.
12. The topical composition of claim 8 wherein the vitamin E is present in an amount up to 3 percent by weight.
13. The topical composition of claim 8 wherein hydrocortisone is present in an amount up to 1 percent by weight.
14. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight, the witch hazel extract is present in an amount up to 50 percent by weight, the green tea leaf extract leaf extract is present in an amount up to 3 percent by weight, the vitamin E is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
15. A method for treating discomfort of the skin including the perianal and vaginal regions, the method comprising administering topically a pharmaceutical composition comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream.
US16/664,477 2016-07-22 2019-10-25 Composition and method for treating itching, burning and discomfort of the skin Abandoned US20200085902A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/664,477 US20200085902A1 (en) 2016-07-22 2019-10-25 Composition and method for treating itching, burning and discomfort of the skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/217,721 US10456438B2 (en) 2016-07-22 2016-07-22 Composition for treating pruritus
US16/664,477 US20200085902A1 (en) 2016-07-22 2019-10-25 Composition and method for treating itching, burning and discomfort of the skin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/217,721 Continuation US10456438B2 (en) 2016-07-22 2016-07-22 Composition for treating pruritus

Publications (1)

Publication Number Publication Date
US20200085902A1 true US20200085902A1 (en) 2020-03-19

Family

ID=60990340

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/217,721 Active 2037-04-23 US10456438B2 (en) 2016-07-22 2016-07-22 Composition for treating pruritus
US16/664,477 Abandoned US20200085902A1 (en) 2016-07-22 2019-10-25 Composition and method for treating itching, burning and discomfort of the skin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/217,721 Active 2037-04-23 US10456438B2 (en) 2016-07-22 2016-07-22 Composition for treating pruritus

Country Status (1)

Country Link
US (2) US10456438B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916183A (en) 2020-01-10 2023-04-04 布里奥里生物技术公司 Topical compositions containing rofecoxib and methods for their preparation and use
CN111743984A (en) * 2020-07-30 2020-10-09 张尚华 Ginseng and cattail-flavor ointment for treating perianal eczema and pruritus and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
BR112015025726A2 (en) * 2013-04-09 2017-07-18 Arch Chem Inc multi-functional makeup for cosmetic formulations

Also Published As

Publication number Publication date
US20180021396A1 (en) 2018-01-25
US10456438B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
JP6473134B2 (en) Flunisolide topical composition and method of treatment
US11331326B2 (en) Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
KR100619228B1 (en) Topical skin delivery anhydrous composition and a composition for topical skin treatment comprising the composition as a medicament
US20220287964A1 (en) Topical formulations comprising cannabidiol, method of prep aring the composition and use thereof
US20130267490A1 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate
US7179475B1 (en) Anhydrous topical skin preparations
EP3677265A1 (en) Composition for preventing or treating sleep disorders
US20220273559A1 (en) Cbd formulations and uses thereof
FI56931B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT THERAPEUTIC ACTIVE STABILT TRETINOINGELPREPARAT UR VILKET TRETINOINET LAETT FRIGOERES OCH ABSORBERAS I HUDEN
US9572777B2 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine
US20030026819A1 (en) Cream-to-powder dermatological composition
US20200085902A1 (en) Composition and method for treating itching, burning and discomfort of the skin
JP2015518886A (en) Method for treating skin inflammatory disease
US8936814B2 (en) Skin cream
US20230108251A1 (en) Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response
CN113924084A (en) pharmaceutical composition
WO2015040637A1 (en) Improved coal tar formulation for treatment of dandruff and other scalp diseases and its method of preparation thereof
KR102751617B1 (en) Composition for preventing, ameliorating or treating rosacea comprising isochlorogenic acid or salts thereof as an active ingredient
RU2426540C1 (en) Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition
KR20090071529A (en) Cosmetic composition having antibacterial and antifungal activity comprising vitamin K 1 or vitamin K 3 as an active ingredient
WO2022113072A1 (en) Topical compositions comprising proton pump inhibitors (ppis) for the treatment of skin disorders
WO2021080527A1 (en) Topical pharmaceutical compositions containing difluocortolone and isoconazole
EP1159956A2 (en) Anhydrous topical skin preparations
KR20150128952A (en) Topical compositions of flunisolide and methods of treatment
WO2016133471A1 (en) A topical composition comprising mupirocin and dexpanthenol

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION